Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced
delivery technologies and development solutions for drugs, biologics and
consumer health products, today announced the addition of three new
members to its Board of Directors and the retirement of Board member
James Quella after nine years of valued service.
Joining the Board are Rosemary A. Crane, John J. Greisch, and Dr.
Christa Kreuzburg. Commenting on the new directors, Chair of the Board
and Chief Executive Officer John Chiminski stated, “We are very excited
to add three accomplished individuals to our Board. Their enormous
collective experience in healthcare and pharmaceutical operations,
finance, and product development will be of substantial benefit to the
entire Board and to Catalent as we continue to mature as a fully
independent public company.”
Commenting on the retirement of Mr. Quella, Mr. Chiminski said, “James
has been an important part of Catalent’s transformation from a private
equity portfolio company to a vibrant and growing leader in
pharmaceutical services. I want to note especially the Board’s
appreciation for his long service on important Board committees,
critically important work that too often goes unsung. We thank James for
all he has given Catalent during his distinguished tenure.”
Ms. Crane, 58, is currently a member of the board of directors of each
of Edge Therapeutics, Inc., Teva Pharmaceutical Industries Limited, and
Zealand Pharma A/S, and has previously served as a director of Unilife
Corporation, Cipher Pharmaceuticals, MELA Sciences, Inc., Epocrates
Inc., and Targanta Therapeutics. Ms. Crane retired in 2014 from MELA
Sciences, Inc., where she served as President and Chief Executive
Officer beginning in 2013. From 2011 to 2013, she was a Partner and Head
of Commercialization at Appletree Partners and, from 2008 to 2011,
served as Chief Executive Officer and President of Epocrates Inc. From
2002 to 2008, Ms. Crane served in several senior executive positions at
the Johnson & Johnson Group of Companies, ending as Company Group
Chairman, OTC and Nutritional Group. From 1982 to 2002, she was at
Bristol-Myers Squibb Company, ending her tenure there as President, U.S.
Primary Care. Ms. Crane received her M.B.A. from Kent State University
and her B.A. in Communications and English from the State University of
New York at Oswego.
Mr. Greisch, 62, has announced his intention to retire later this year
from his current position as President and Chief Executive Officer of
Hill-Rom Holdings, Inc., a position that he has held since 2010. Prior
to his current position, Mr. Greisch was President International
Operations for Baxter International, Inc., a position he held beginning
in 2006. During his seven-year tenure with Baxter, he also served as
Baxter’s Chief Financial Officer and as President of Baxter’s BioScience
division. Before his time with Baxter, Mr. Greisch was President and
Chief Executive Officer for FleetPride Corporation in Deerfield,
Illinois, an independent after-market distribution company serving the
transportation industry. Prior to his tenure at FleetPride, he held
various positions at The Interlake Corporation, including serving as
President of its Materials Handling Group. Mr. Greisch currently serves
on the board of directors of Hill-Rom Holdings, Inc., Idorsia
Pharmaceuticals Ltd. and AdvaMed, and previously served on the board of
directors of Actelion Ltd. Additionally, he is on the board of directors
for Ann & Robert H. Lurie Children’s Hospital of Chicago. Through
January 2010, Mr. Greisch served as a director of TomoTherapy, Inc. He
received a Masters in Management from the Kellogg School of Management
at Northwestern University and a B.S. degree from Miami University.
Dr. Kreuzburg, 58, has been consulting in the healthcare sector since
retiring from Bayer AG in 2009 after 19 years of service in a variety of
roles, including serving as Head of the Bayer Schering Pharma
Europe/Canada unit of Bayer Healthcare from 2007 to 2008 and as Head of
the Pharma Primary Care/International Operations unit of Bayer
Healthcare from 2006 to 2007. She also held roles in the Strategic
Planning and Central Research groups. Dr. Kreuzburg is currently a
member of the board of directors of Tecan Trading AG of Switzerland as
well as chairwoman of its compensation committee and has previously
served as a director of Freedom Innovations LLC. She received her Ph.D.
and Bachelor’s degrees in Physical Chemistry from Duisburg University in
Germany.
About Catalent, Inc.
Catalent, Inc. (NYSE: CTLT) is the leading global provider of advanced
delivery technologies and development solutions for drugs, biologics and
consumer health products. With over 80 years serving the industry,
Catalent has proven expertise in bringing more customer products to
market faster, enhancing product performance and ensuring reliable
clinical and commercial product supply. Catalent employs over 11,000
people, including over 1,400 scientists, at more than 30 facilities
across 5 continents and in fiscal 2017 generated over $2 billion in
annual revenue. Catalent is headquartered in Somerset, N.J. For more
information, please visit
www.catalent.com
.
More products. Better treatments. Reliably supplied.™
Investor:
Catalent, Inc.
Thomas Castellano, 732-537-6325
investors@catalent.com